Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
The 2024 CDC numbers around national health care costs attributable to diabetes are staggering, making it the most expensive chronic condition in the U.S.: $1 out of every $4 in U.S
In the metabolism of food and generation of energy
Not intended to diagnose, treat, cure or prevent any disease
Stacking GHK-Cu with other therapies can deliver synergistic results by addressing hair loss from multiple angles
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
US$ 29.76
US$ 20.62
US$ 28.21
US$ 22.07
